WATCHconviction 3published 2026-09-10

TILE — Interface, Inc. · 2026-09-10 · Verdict: WATCH · Conviction 3

Price $34.51 (screen row, QUALITY.md build dated 2026-09-10; no live price) · Mkt cap $1.99B · EV $2.12B · EV/normalised EBIT 11.5x · FCF yield 6.1% · Net debt $(122.8)M · ADV $19.1M Sources read: 10-K 2026-02-25 (Items 1, 1A, 7), 10-Q 2026-08-11, DEF 14A 2026-04-01, 8-Ks 2026-05-08, 2026-06-04, 2026-08-07, 2026-08-11, Form 4s (12m to 2026-09-04). No transcript in the bundle; management quotes from the Q2 release (8-K 2026-08-07, EX-99.1).

Desk stats

1. What the business actually does

Interface makes commercial flooring: modular carpet tile (Interface, FLOR), luxury vinyl tile, and nora rubber flooring acquired in 2018 (10-K, Item 1). Two segments, Americas 61% of FY2025 sales and EAAA 39%. Carpet tile is made in the US, Netherlands, UK, China and Australia; rubber in Weinheim, Germany; LVT entirely by a third party in South Korea. More than half of sales are now non-corporate-office (education, healthcare, public buildings, retail, transportation), the result of a decade of deliberate diversification away from the office cycle. Sustainability is a commercial asset rather than a slide: 200-plus cradle-to-gate carbon negative styles, and specification influence with the architects who write flooring into a job.

2. Why it is mispriced: the edge case

There is not a durable one, which caps this at WATCH. The screen gap is mechanical: 17.1x was computed on stale FY2025 operating income and the true figure is 15.3x. That is arithmetic, not insight. No forced sellers, no spin-off, no index deletion, no coverage vacuum. Ownership is the opposite of neglected, with BlackRock at 15.35% and Vanguard at 10.01% as of 2026-03-13, the iShares Core S&P Small-Cap ETF alone above 5% (DEF 14A), and $19.1M of daily volume. The stock is up 26% over six months and 12% below its 52-week high. The one fact a reader may not hold is that the August quarter's optics are inflated by a tariff refund, which argues the stock is less cheap than the tape suggests, not more.

3. Unit economics and growth

The improvement is real and sits in gross margin: 35.0% in FY2023, 36.7% in FY2024, 38.7% in FY2025, on pricing, mix and fixed-cost absorption (10-K, Item 7). Q2 2026 adjusted gross margin rose 524 basis points, but management splits that itself into 131 basis points of operational gain and 393 from the refund (8-K 2026-08-07). EAAA holds the leverage: segment AOI margin went from 5.2% to 9.4% in the quarter on 4.5% currency-neutral growth, while AMS reached 24.6%. Three-year cumulative ROIC was 14.8% against a 14.1% goal (DEF 14A). FY2025 free cash flow was $121.7M from $167.9M of operating cash flow less $46.2M of capex, so conversion against normalised after-tax profit is near one. Currency-neutral orders grew 5.4% in Q2, the cleanest forward read available. Backlog was $269.1M at 2026-07-20 against $222.8M at 2026-02-02, but those dates are not comparable and the February figure was flat year over year ($222.8M versus $223.4M), so backlog is not evidence of acceleration. Concentration is on the supply side: a few nylon yarn suppliers and one primary LVT manufacturer in South Korea (Item 1A).

4. Balance sheet and capital allocation

In December 2025 Interface redeemed all $300M of its 5.50% Senior Notes with a new $170M term loan, taking guided FY2026 interest expense to about $10M from $19.5M incurred in FY2025 (10-K, Item 7). Total debt $204.4M, cash $81.5M, net leverage 0.52x, $216.3M undrawn (10-Q). Buybacks restarted after two idle years: 750,166 shares at $24.23 in FY2025 and 771,125 at $26.90 in H1 2026, with $64.7M of authorisation left. Both tranches were bought well below today's price. Insiders run the other way: trailing-twelve-month Form 4s show zero open-market purchases and about $4.1M of sales by seven insiders, including CEO Hurd (7,000 at $39.09), CFO Hausmann (50,000 at $29.66), the general counsel (44,393 at $29.00) and director Daniel Hendrix (8,000 at $37.13 on 2026-09-02). Officers and directors hold 2.47% in aggregate. Caveat: the Hendrix sale appears twice in the bundle across two accessions on identical terms, so the raw $4.45M total double-counts about $297K.

5. Management: what they said versus what they did

They have beaten their own guidance all year and named which part was luck. Q2 guidance given 2026-05-08 was $385-395M at 39.9% adjusted gross margin; they delivered $395.7M and 45.0%, and led the release with the execution-versus-refund split. Full-year sales guidance went from $1.420-1.460B to $1.450-1.480B to $1.455-1.485B, and full-year adjusted gross margin from 38.5-39.0% to 40.6%, of which about 106 basis points is the refund, leaving roughly 60 basis points of operational raise. Credible. One alignment note: 85% of the annual bonus is adjusted operating income, which as defined excludes only restructuring, severance and purchase accounting, so the $15.6M refund sits inside the bonus metric. The June 2026 amendment lifting the maximum individual bonus from $1.85M to $3.0M (8-K 2026-06-04) came in the same year as the windfall.

6. Valuation

Bear, 25%: corporate office rolls back over (it led Q2 growth, so it is the swing factor), the euro tailwind reverses, and the higher raw material, energy and LVT costs management flagged for H2 bite with no further refund. FY2027 sales $1.42B, gross margin 37.5%, SG&A sticky at $395M, operating income $138M, after-tax $103M at 12x, less $130M net debt: about $19. Base, 55%: FY2027 sales $1.50B (4% on a 52-week-equivalent FY2026 base near $1.44B), gross margin 39.8%, SG&A 26.8% of sales, operating income $195M, after-tax $146M at 15x, less $90M net debt: about $37. Bull, 20%: the 131 basis points of operational gain compounds and mix keeps shifting to healthcare and education, giving FY2028 sales of $1.62B at 41.0% gross margin, operating income $238M, after-tax $178M at 17x on no net debt: about $54. Probability-weighted, $35.8 against $34.51, roughly 4% upside and no margin of safety. Reverse DCF: at $34.51, EV of $2,117.5M against $138.4M of normalised after-tax profit is a 6.5% yield, so at a 9% cost of capital the price implies about 2.5% perpetual growth, inflation and nothing more. Not a demanding hurdle, which is the bull's best argument; also already a fair price for a cyclical, which is the bear's.

7. Catalysts and timeline

Q3 results in early November, against guidance of $370-380M at 40.8% adjusted gross margin, are the first clean read with no refund in the number; holding 40%-plus ex-refund resets the base case upward. Q4 brings the annual nora trademark impairment test, where FY2025 testing showed headroom a 10% revenue shortfall would not erase (10-K, Item 7). The $64.7M of remaining buyback authorisation is steady support. Longer-dated: whether the EAAA margin move from 5.2% to 9.4% proves structural.

8. Risks and pre-registered kill criteria

  1. Adjusted gross margin below 39.0% for two consecutive quarters. The thesis is that the 131 basis points of operational gain is durable; two quarters under 39% says the refund was the story.
  2. Currency-neutral orders negative year over year in any quarter. Orders are the cleanest lead on the commercial-interiors cycle and were +5.4% in Q2.
  3. Net leverage above 1.5x, or a debt-funded acquisition. The 0.5x balance sheet is much of why 15x is defensible.
  4. Insider open-market selling above $5M in a rolling twelve months with still no purchases. Seven sellers and zero buyers is already a caution.

9. Verdict and one-paragraph summary

WATCH, conviction 3. Interface is a genuinely better business than three years ago and the improvement is not accounting: gross margin has gone from 35.0% to 38.7% across FY2023-FY2025 on pricing, mix and factory productivity, the $300M of 5.50% notes are gone so interest expense falls from $19.5M toward $10M, net leverage is 0.52x, three-year ROIC was 14.8%, free cash flow converts nearly one-for-one, and management raised guidance three times this year while stating candidly that 393 of the quarter's 524 basis points of margin beat came from a one-off tariff refund rather than execution. None of this is secret. The screen's 17.1x was simply stale; the real multiple is 15.3x EV to normalised after-tax operating profit, which at a 9% cost of capital implies only 2.5% perpetual growth, a low bar but not a mispricing. A probability-weighted $35.8 sits about 4% above the $34.51 screen price, while the stock is up 26% in six months, 12% off its high, a quarter of it owned by BlackRock and Vanguard, and sold by seven insiders including the CEO, CFO and general counsel at $29 to $39 with not one open-market purchase against them. A good company at a fair price, bought back by the company below today's level and sold by its managers above it. Worth owning after a cyclical scare or a clean 40%-plus gross margin quarter with no refund in it, not worth paying up for today.

Research for discussion, not investment advice. Positions and sizing are the reader's decision.

Source markdown: 2026-09-10_TILE.md · how these notes are built · every verdict tracked since publication.

Research and education only. Nothing here is investment advice or a recommendation to buy or sell any security. No price targets are recommendations; positions and sizing are the reader's decision. Past performance does not predict future results.